Shots:
- Alvotech has entered into a supply & commercialization agreement with Advanz Pharma for AVT10, a biosimilar version of Cimzia (certolizumab pegol)
- Alvotech & Advanz Pharma have previously partnered on biosimilars for over 10 reference biologics, with a plan to launch their first biosimilars in the EU by Q4’25
- Cimzia binds with both soluble & membrane-bound TNF-alpha to block its inflammatory signaling without triggering complement or antibody-dependent cytotoxicity due to the lack of its Fc region
Ref: GlobeNewsWire | Image: Alvotech & Advanz Pharma | Press Release
Related News:- Alvotech & Advanz Pharma Secure the CHMP’s Positive Opinion for AVT06 (Biosimilar, Eylea)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
